Deep Track Capital Increases Stake in Structure Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: Fool
- Stake Increase: Deep Track Capital disclosed an acquisition of 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's growth potential.
- Ownership Proportion: Following this purchase, Deep Track's stake in Structure rose to 3.37%, representing a significant position within its $6.12 billion reportable U.S. equity holdings, highlighting the fund's commitment to the company.
- Market Performance: As of last Friday, Structure Therapeutics' shares were priced at $39.19, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 28% rise, suggesting strong market optimism regarding its future.
- R&D Progress: The company reported a Phase 2 trial for its oral GLP-1 candidate aleniglipron showing up to 16.3% weight loss, with plans to initiate Phase 3 studies in Q3 2026, which could solidify its competitive position in the obesity market if successful.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GPCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.190
Low
65.00
Averages
106.50
High
140.00
Current: 39.190
Low
65.00
Averages
106.50
High
140.00
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Deep Track Capital Increases Stake in Structure Therapeutics
- Stake Increase: Deep Track Capital disclosed an acquisition of 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's growth potential.
- Ownership Proportion: Following this purchase, Deep Track's stake in Structure rose to 3.37%, representing a significant position within its $6.12 billion reportable U.S. equity holdings, highlighting the fund's commitment to the company.
- Market Performance: As of last Friday, Structure Therapeutics' shares were priced at $39.19, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 28% rise, suggesting strong market optimism regarding its future.
- R&D Progress: The company reported a Phase 2 trial for its oral GLP-1 candidate aleniglipron showing up to 16.3% weight loss, with plans to initiate Phase 3 studies in Q3 2026, which could solidify its competitive position in the obesity market if successful.
See More
Deep Track Capital Increases Stake in Structure Therapeutics
- Stake Increase: Deep Track Capital acquired an additional 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's future value creation potential.
- Decline in Position Value: Despite the increase, the quarter-end position value decreased by $79.69 million, reflecting the dual impact of trading activity and stock price fluctuations, highlighting market concerns about the stock's volatility.
- Clinical Advancements: Structure Therapeutics' oral GLP-1 candidate aleniglipron demonstrated a weight loss of up to 16.3% in Phase 2 trials, potentially comparable to injectable therapies, enhancing its competitiveness in the obesity market.
- Strong Financial Position: The company ended the quarter with approximately $1.5 billion in cash and short-term investments, sufficient to support operations through the end of 2028, showcasing a robust financial foundation for R&D and market expansion.
See More
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape
- Stake Reduction Details: Monashee Investment Management reduced its holdings in Structure Therapeutics by 175,000 shares in Q1 2026, with an estimated transaction value of $11.98 million, resulting in a $13.24 million decrease in its GPCR position, indicating a cautious outlook on the company's future potential.
- Holding Proportion Analysis: Post-reduction, Monashee's remaining stake accounts for 1.8% of its 13F reportable assets, suggesting a diminished confidence in the company despite its strong performance in clinical testing.
- Market Competition Landscape: The GLP-1 weight loss drug market is highly competitive, and while Structure's oral therapies show promising results in trials, numerous pharmaceutical companies are developing similar products, increasing future uncertainty.
- Investor Strategy Recommendation: Given Monashee's reduction, investors may prefer ETFs that encompass the GLP-1 sector, such as the Roundhill GLP-1 & Weight Loss ETF, to diversify risk and capture market opportunities.
See More
HighVista Strategies Sells Shares of Structure Therapeutics
- Share Reduction Transaction: HighVista Strategies sold 69,092 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $4.73 million, indicating a potential shift in confidence regarding the company.
- Decline in Position Value: This sale resulted in a $7.45 million decrease in HighVista's position value in Structure Therapeutics, highlighting the impact of market price fluctuations on its investment portfolio.
- Strong Company Performance: As of May 14, 2026, Structure Therapeutics' shares were priced at $39.84, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its future potential.
- Positive Clinical Progress: Structure Therapeutics reported promising Phase 2 data for its oral obesity candidate aleniglipron, showing up to 16.3% placebo-adjusted weight loss at 44 weeks, underscoring its competitive edge in the GLP-1 therapy market.
See More
ACT Capital Management Fully Exits Structure Therapeutics Stake
- Complete Exit: ACT Capital Management sold all 38,500 shares of Structure Therapeutics in Q1 2026, with an estimated trade value of $2.63 million, indicating a full exit that reflects a cautious stance amid biotech market volatility.
- Net Position Change: The transaction resulted in a $2.68 million decrease in ACT's net position, suggesting that after a significant price increase, management opted to lock in profits at a high point to mitigate potential market risks.
- Strong Company Performance: As of May 7, 2026, Structure Therapeutics shares were priced at $39.15, up 47% over the past year, outperforming the S&P 500 by 17 percentage points, highlighting its robust growth potential in chronic disease treatment.
- Strong Financial Position: Structure ended the quarter with approximately $1.5 billion in cash and short-term investments, which is expected to fund operations through the end of 2028, enhancing its competitive edge in future product development and commercialization.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
Deep Track Capital Increases Stake in Structure Therapeutics
- Stake Increase: Deep Track Capital disclosed an acquisition of 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's growth potential.
- Ownership Proportion: Following this purchase, Deep Track's stake in Structure rose to 3.37%, representing a significant position within its $6.12 billion reportable U.S. equity holdings, highlighting the fund's commitment to the company.
- Market Performance: As of last Friday, Structure Therapeutics' shares were priced at $39.19, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 28% rise, suggesting strong market optimism regarding its future.
- R&D Progress: The company reported a Phase 2 trial for its oral GLP-1 candidate aleniglipron showing up to 16.3% weight loss, with plans to initiate Phase 3 studies in Q3 2026, which could solidify its competitive position in the obesity market if successful.
See More
Deep Track Capital Increases Stake in Structure Therapeutics
- Stake Increase: Deep Track Capital acquired an additional 168,066 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $11.50 million, indicating confidence in the company's future value creation potential.
- Decline in Position Value: Despite the increase, the quarter-end position value decreased by $79.69 million, reflecting the dual impact of trading activity and stock price fluctuations, highlighting market concerns about the stock's volatility.
- Clinical Advancements: Structure Therapeutics' oral GLP-1 candidate aleniglipron demonstrated a weight loss of up to 16.3% in Phase 2 trials, potentially comparable to injectable therapies, enhancing its competitiveness in the obesity market.
- Strong Financial Position: The company ended the quarter with approximately $1.5 billion in cash and short-term investments, sufficient to support operations through the end of 2028, showcasing a robust financial foundation for R&D and market expansion.
See More
Monashee Reduces Stake in Structure Therapeutics Amid Competitive Landscape
- Stake Reduction Details: Monashee Investment Management reduced its holdings in Structure Therapeutics by 175,000 shares in Q1 2026, with an estimated transaction value of $11.98 million, resulting in a $13.24 million decrease in its GPCR position, indicating a cautious outlook on the company's future potential.
- Holding Proportion Analysis: Post-reduction, Monashee's remaining stake accounts for 1.8% of its 13F reportable assets, suggesting a diminished confidence in the company despite its strong performance in clinical testing.
- Market Competition Landscape: The GLP-1 weight loss drug market is highly competitive, and while Structure's oral therapies show promising results in trials, numerous pharmaceutical companies are developing similar products, increasing future uncertainty.
- Investor Strategy Recommendation: Given Monashee's reduction, investors may prefer ETFs that encompass the GLP-1 sector, such as the Roundhill GLP-1 & Weight Loss ETF, to diversify risk and capture market opportunities.
See More
HighVista Strategies Sells Shares of Structure Therapeutics
- Share Reduction Transaction: HighVista Strategies sold 69,092 shares of Structure Therapeutics in Q1 2026, with an estimated transaction value of $4.73 million, indicating a potential shift in confidence regarding the company.
- Decline in Position Value: This sale resulted in a $7.45 million decrease in HighVista's position value in Structure Therapeutics, highlighting the impact of market price fluctuations on its investment portfolio.
- Strong Company Performance: As of May 14, 2026, Structure Therapeutics' shares were priced at $39.84, reflecting a 60% increase over the past year, significantly outperforming the S&P 500's 25% gain, indicating strong market recognition of its future potential.
- Positive Clinical Progress: Structure Therapeutics reported promising Phase 2 data for its oral obesity candidate aleniglipron, showing up to 16.3% placebo-adjusted weight loss at 44 weeks, underscoring its competitive edge in the GLP-1 therapy market.
See More
ACT Capital Management Fully Exits Structure Therapeutics Stake
- Complete Exit: ACT Capital Management sold all 38,500 shares of Structure Therapeutics in Q1 2026, with an estimated trade value of $2.63 million, indicating a full exit that reflects a cautious stance amid biotech market volatility.
- Net Position Change: The transaction resulted in a $2.68 million decrease in ACT's net position, suggesting that after a significant price increase, management opted to lock in profits at a high point to mitigate potential market risks.
- Strong Company Performance: As of May 7, 2026, Structure Therapeutics shares were priced at $39.15, up 47% over the past year, outperforming the S&P 500 by 17 percentage points, highlighting its robust growth potential in chronic disease treatment.
- Strong Financial Position: Structure ended the quarter with approximately $1.5 billion in cash and short-term investments, which is expected to fund operations through the end of 2028, enhancing its competitive edge in future product development and commercialization.
See More
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
- Strong Buy Rating: Raymond James reiterated a 'Strong Buy' rating on Viking Therapeutics (VKTX) with a $118 price target, implying a substantial 258% upside, reflecting analysts' strong confidence in the company's future performance.
- Financial Expectations: Consensus estimates anticipate VKTX will report a GAAP loss per share of $1.03, widening from last year's $0.4 loss, with projected EBITDA losses nearing $129.5 million, indicating ongoing financial pressures as the company remains in the clinical stage.
- Clinical Trial Progress: Investor focus remains on the ongoing Phase 3 Vanquish obesity treatment program, with enrollment for the second phase completed in March and results from a maintenance-dose study expected in Q3, highlighting strong demand for new treatment options.
- Intensifying Market Competition: As emerging biotech firms and large pharma companies expand their obesity drug pipelines, competition is intensifying, with Viking facing challenges from companies like Structure Therapeutics and Altimmune, while Eli Lilly's new drug Foundayo shows slower initial prescription data.
See More
